Impact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis
Pharmacoepidemiology · 26.03.2026 · 5 (2) · 10
DOI: 10.3390/pharma5020010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology, online erschienen am 26.03.2026. Verfasst von Diana Toledo und 8 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Catalan Agency for the Management of Grants for Universities—AGAUR https://ror.org/01n4pqe45.
Abstract (Originalsprache)
Background/Objectives: The study’s goal is to assess the association between long-term statin therapy and influenza incidence, influenza severity, and all-cause mortality.
Methods
Two population-based dynamic cohorts (exposed and unexposed to statins) were followed from 2010 to 2019. Participants were 60 years or older; frail patients were excluded. The primary outcomes were influenza incidence, influenza-related intensive care unit (ICU) admission as a proxy for severity, and all-cause mortality. The exposed cohort comprised new statin users with a minimum of two pharmacy invoices within 90 days of enrollment. Adjusted risk ratios (aRRs) for influenza incidence, ICU admission, and mortality rate were calculated using Poisson regression.
Results
The initial study population of 639,564 individuals was evenly split into exposed (319,782) and unexposed (319,782) cohorts; mean age was 71 years (standard deviation: 8 years), and 57% were women. Compared to non-users, new statin users showed a higher influenza incidence [9.39 (95% confidence interval: 9.36–9.42) vs. 7.64 (7.61–7.66) per 1000 person-years], ICU admission [1.65 (1.65–1.66) vs. 1.36 (1.35–1.36) per 1000 person-years], and overall mortality rate [97.09 (96.75–97.43) vs. 94.15 (93.82–94.47) per 1000 person-years]. Adjusted analysis revealed no significant association between statin use and influenza incidence [aRR: 1.04 (0.98–1.10)] or influenza-related ICU admission [aRR: 1.03 (0.89–1.19)] and shifted the effect on mortality from harmful to beneficial [aRR: 0.88 (0.87–0.89)].
Conclusions
Despite new users’ greater vulnerability at the start of treatment, our findings indicate that statins do not influence influenza incidence or severity but reduce all-cause mortality, warranting further exploration of their anti-inflammatory properties.
Förderung
- Catalan Agency for the Management of Grants for Universities—AGAUR https://ror.org/01n4pqe45
Zitieren
APA
Toledo, D., Cartanyà-Hueso, À., Pagès-Fernández, C., Morros, R., Giner-Soriano, M., Domínguez, À., Vilaplana-Carnerero, C., Tor-Roca, A., & Grau, M. (2026). Impact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis. Pharmacoepidemiology, 5(2), 10. https://doi.org/10.3390/pharma5020010
Vancouver
Toledo D, Cartanyà-Hueso À, Pagès-Fernández C, Morros R, Giner-Soriano M, Domínguez À, et al. Impact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis. Pharmacoepidemiology. 2026;5(2):10. doi:10.3390/pharma5020010
BibTeX
@article{Toledo2026,
author = {Toledo, Diana and Cartanyà-Hueso, Àurea and Pagès-Fernández, Constança and Morros, Rosa and Giner-Soriano, Maria and Domínguez, Àngela and Vilaplana-Carnerero, Carles and Tor-Roca, Alba and Grau, María},
title = {Impact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis},
journal = {Pharmacoepidemiology},
year = {2026},
volume = {5},
number = {2},
pages = {10},
doi = {10.3390/pharma5020010}
}
EUVIMED